Abstract 1577P
Background
Antibiotic therapy has been known to disrupt microbiota homeostasis and systemic immune responses, both of which are linked to response to immune checkpoint blockade. We aim to investigate whether prior antibiotics (pATB) administration influences outcomes following treatment with programmed cell death protein-1 (PD-1) inhibitors or chemotherapy in patients with advanced gastric cancer (AGC).
Methods
We analysed data of patients with AGC who were treated with PD-1 inhibitors (retrospective exploratory cohort; n=152) or irinotecan (chemotherapy cohort; n=101). Patients were classified into two groups based on whether they had received pATB within 28 days prior to the treatment. Another independent retrospective validation cohort (n=123) and prospective validation cohort (n=30) treated with PD-1 inhibitors were further analysed. Distinct features in gut microbiome and circulating immune cells were analysed (experimental cohort; n=24).
Results
In the retrospective exploratory cohort, pATB administration was associated with poor 17 progression-free survival (PFS; hazard ratio [HR]=2.897, 95% confidence interval [CI]=2.043–4.109) and overall survival (OS; HR=2.294, 95% CI=1.622–3.242) but did not affect outcomes among patients treated with irinotecan. In the validation cohorts, pATB administration was associated with poor treatment outcomes following PD-1 blockade. Multivariate analysis of the overall patients treated with PD-1 inhibitors confirmed that pATB was an independent predictor of poor PFS (HR=3.243, 95% CI=2.427–4.333) and OS (HR=3.046, 95% CI= 2.358–3.935). Administration of pATB was associated with diminished gut microbiome diversity, reduced abundance of Lactobacillus gasseri, and disproportional enrichment of circulating exhaustive CD8+ T cells, all of which can hinder the efficacy of PD-1 blockade.
Conclusions
Considering the inferior treatment response and poor survival outcomes by pATB followed by PD-1 blockade, antibiotics should be prescribed with caution in patients with AGC planned to receive PD-1 inhibitors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Research Foundation of Korea, Ministry of Science and ICT, Yonsei University College of Medicine.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1701P - Cancer premium: Explaining differences in prices for cancer vs non-cancer drugs with efficacy and epidemiological endpoints in the US, Germany, and Switzerland
Presenter: Miquel Serra-Burriel
Session: Poster session 22
1702P - Real-world evidence contributions to European medicines agency’s safety and efficacy evaluations of oncology targeted therapies between 2018-2022
Presenter: Jeroen W. G. Derksen
Session: Poster session 22
1703P - Value of molecular targets and genome-targeted cancer therapies FDA-approved, 2015-2022
Presenter: Ariadna Tibau
Session: Poster session 22
1704P - Clinical benefit of cancer drugs approved by the US food and drug administration based on appropriateness of control arm and its change over time
Presenter: Molto Consolacion
Session: Poster session 22
1705P - Therapeutic value of first vs supplemental indications of drugs in the US and Europe (2011-2020): Retrospective cohort study
Presenter: Kerstin Vokinger
Session: Poster session 22